GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Current Deferred Revenue

Longevity Biomedical (Longevity Biomedical) Current Deferred Revenue : $0.00 Mil (As of . 20)


View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Longevity Biomedical's current deferred revenue for the quarter that ended in . 20 was $0.00 Mil.

Longevity Biomedical Current Deferred Revenue Historical Data

The historical data trend for Longevity Biomedical's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Current Deferred Revenue Chart

Longevity Biomedical Annual Data
Trend
Current Deferred Revenue

Longevity Biomedical Semi-Annual Data
Current Deferred Revenue

Longevity Biomedical Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Biomedical (Longevity Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines